Steve Chamow

Biochemistry PhD and Drug Developer
Steve Chamow
As a biochemistry PhD with more than 30 years of experience in the field of drug discovery, Steve knows what it takes to develop pharmaceuticals and take them to market.
No items found.
No items found.

PAST EVENTS

Technologies for Vaccines for COVID-19

What Does It Take to Develop a New Drug for COVID-19?

Thursday, April 16th, 6-7pm PT / 9-10pm ET

Dr. Steve Chamow is back by popular demand for an extended conversation on COVID-19 drug discovery. Join us to learn more about the availability of technologies for therapeutics and vaccines and opportunities to shorten the timeline of clinical drug development.

We're eager to learn from drug development expert Dr. Steve Chamow about what it will take to make drugs to treat COVID-19.

Technologies for Vaccines for COVID-19

What Does It Take to Develop a New Drug for COVID-19?

Tuesday, May 7th, 5-6:30pm PT / 8-9:30pm ET

Dr. Steve Chamow is back by popular demand for an extended conversation on COVID-19 drug discovery. Join us to learn more about the availability of technologies for therapeutics and vaccines and opportunities to shorten the timeline of clinical drug development.

The current pandemic is affecting our lives in ways we never expected, and scientists around the globe are working to stop its spread. In this timely talk with Dr. Steve Chamow, we'll learn about what it will take for drug companies to mitigate the impact of coronavirus.

Technologies for Vaccines for COVID-19

Technologies for Vaccines for COVID-19

Tuesday, May 19th, 5-6:30pm PT / 8-9:30pm ET

Dr. Steve Chamow is back by popular demand for an extended conversation on COVID-19 drug discovery. Join us to learn more about the availability of technologies for therapeutics and vaccines and opportunities to shorten the timeline of clinical drug development.

Dr. Steve Chamow is back by popular demand for an extended conversation on COVID-19 drug discovery. Join us to learn more about the availability of technologies for therapeutics and vaccines and opportunities to shorten the timeline of clinical drug development.

Bio

Dr. Steven Chamow has over 30 years of experience in biopharmaceutical product development. Since 2008, he has served as president of Chamow & Associates, Inc., a consulting group working with biotechnology companies to design and implement strategies to develop new therapeutic products.

In his career, he has contributed to the development of three marketed biologics (Avastin, Natrecor, Vectibix). Prior to his current position, he was Senior Vice President, CMC, at Intradigm Corporation, a private biopharmaceutical company focused on developing RNAi therapeutics (acquired by Silence Therapeutics). Dr. Chamow was Vice President, Process Sciences, at Genitope Corporation and at Abgenix, Inc., (acquired by Amgen) where he built the company’s process sciences department and helped to lead the design and construction of Abgenix’s award-winning production facility in Fremont, CA (sold by Amgen to Boehringer-Ingelheim to become its first North American production facility). Before Abgenix, he served as Director of Biopharmaceutical Development at Scios, Inc. (acquired by J&J), and as a scientist and senior scientist in process development at Genentech, Inc. (acquired by Roche).

Dr. Chamow was educated at the University of California (UC Santa Cruz, B.A. in biology; UC Davis, Ph.D. in biochemistry), and completed postdoctoral training at the National Institutes of Health in Bethesda, MD. He is author or co-author of more than 50 scientific publications and patents and co-editor of two books.

Reviews

"Steve was very clear and personable. I appreciated his insights and expertise and the plain spoken approach he took to a very complex topic!"

Speakeasy participant

"Excellent and informative."

Speakeasy participant

"Steve's talk was informative and understandable. I appreciated being able to go over the hour mark in order to have many more questions answered."

Speakeasy participant